Recruiting

Phase 2

LY4005130A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

Sponsor:

Eli Lilly and Company

Code:

NCT07533019

Conditions

Vitiligo

Non-Segmental Vitiligo (NSV)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

LY4005130

Placebo

Study Details

Brief summary:

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

The study will last approximately 48 weeks, including screening.

Conditions

Vitiligo

Non-Segmental Vitiligo (NSV)

Study ID

NCT07533019

Start date

Apr 14, 2026

Status verified date

Sep, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Eligible participants must have the following at both screening and baseline:

A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months
Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet
BSA involvement of ≥0.5% on the face
F-VASI ≥0.5 and T-VASI ≥3, and
Either active or stable disease at both screening and baseline

Exclusion Criteria:

Participants who have other types of vitiligo that are not considered active or stable vitiligo
Currently have active forms of other disorders of pigmentation
Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment
Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved
Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening
Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data
Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve

Study Design

Enrollment

66 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: LY4005130

LY4005130 administered intravenously (IV)

placebo comparator: Placebo

Placebo administered IV

Interventions

LY4005130

Administered IV

Placebo

Administered IV

Primary outcome measure

Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75 [ Time Frame: Week 24 ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559 LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Medical Dermatology Specialists

Recruiting

Phoenix, Arizona, United States, 85006

Contacts

602-354-5770

Principal Investigator:

Lindsay Ackerman

Saguaro Dermatology - Phoenix

Recruiting

Phoenix, Arizona, United States, 85008

Contacts

480-562-3610

Principal Investigator:

Dathan Hamann

Center For Dermatology Clinical Research, Inc.

Recruiting

Fremont, California, United States, 94538

Contacts

510-797-0140

Principal Investigator:

Sunil Dhawan

Northridge Clinical Trials

Recruiting

Northridge, California, United States, 91325

Contacts

818-350-7482

Principal Investigator:

Navid Ezra

Cura Clinical Research - Oxnard

Recruiting

Oxnard, California, United States, 93030

Contacts

833-525-2872

Principal Investigator:

Michael Lin

Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway

Recruiting

Santa Clarita, California, United States, 91355

Contacts

833-525-2872

Principal Investigator:

Bernard Raskin

Health Clinical Research, LLC

Recruiting

Miami, Florida, United States, 33189

Contacts

786-280-1977

Principal Investigator:

Soroush Aghigh

K2 Medical Research - Tampa

Recruiting

Tampa, Florida, United States, 33634

Contacts

813-800-5252

Principal Investigator:

Kelley Wilson

Advanced Medical Research, PC.

Recruiting

Sandy Springs, Georgia, United States, 30328

Principal Investigator:

Jamie Weisman

Dawes Fretzin Clinical Research Group, LLC

Recruiting

Indianapolis, Indiana, United States, 46250

Contacts

317-516-5030

Principal Investigator:

Scott Fretzin

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

617-732-4918

Principal Investigator:

Arash Mostaghimi

Revival Research Institute, LLC

Recruiting

Troy, Michigan, United States, 48084

Contacts

248-590-0298

Principal Investigator:

Ali Moiin

Stracskin

Recruiting

Portsmouth, New Hampshire, United States, 03801

Contacts

617-833-9995

Principal Investigator:

Abel Jarell

Equity Medical

Recruiting

The Bronx, New York, United States, 10455

Contacts

332-223-6128

Principal Investigator:

Maira Fonseca

Accurate Clinical Research, Inc

Recruiting

Humble, Texas, United States, 77346

Contacts

281-760-3930

Principal Investigator:

Chinelo Fangtang

Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue

Recruiting

San Antonio, Texas, United States, 78235

Contacts

210-852-2779

Principal Investigator:

John Browning

Jordan Valley Dermatology & Research Center

Recruiting

South Jordan, Utah, United States, 84095

Principal Investigator:

Douglass Forsha

Clinical Research Partners, LLC

Recruiting

Richmond, Virginia, United States, 23226

Contacts

804-477-3045

Principal Investigator:

Robert Call

INTERMED Groupe Sante

Recruiting

Chicoutimi, Canada, G7H 7Y8

Contacts

418-602-6620

Principal Investigator:

Doria Grimard

DermEffects

Recruiting

London, Canada, N6H 5L5

Contacts

519-204-6868

Principal Investigator:

Wei Jing Loo

Dar Clinical Research - Ottawa - Hunt Club Road

Recruiting

Ottawa, Canada, K1V 1C1

Principal Investigator:

Reetesh Bose

The Centre for Dermatology

Recruiting

Richmond Hill, Canada, L4B 1A5

Principal Investigator:

Mani Raman

Research Toronto

Recruiting

Toronto, Canada, M4W 2N4

Contacts

4169620123

Principal Investigator:

Sameh Hanna

More Information

Sponsor

Eli Lilly and Company

Last update posted

Sep 22, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-07. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-09-22. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.